Introduction
The triptans, serotonin receptor B/D agonists, are the mainstay in the acute treatment of migraine [1] . Sumatriptan, the first triptan, was originally developed as a cranial vasoconstrictor by acting on the 5-HT1B/1D receptors in cephalic vessels [2] . However, several modes of action as well as multiple sites of action have been proposed. [3] Objectives To explore a possible differential effect of sumatriptan on extra-versus intracerebral arteries, we examined the superficial temporal (STA), middle meningeal (MMA), extracranial internal carotid (ICAextra), intracranial internal carotid (ICAintra), middle cerebral (MCA) and basilar artery (BA).
Methods
The arterial circumference were recorded by high resolution magnetic resonance angiography before and after subcutaneous sumatriptan injection (6 mg) in 18 healthy volunteers.
Results
We found significant constrictions of MMA (16.5%), STA (16.4%), ICAextra (15.2%), MCA (5.5%) and BA (2.1%) (p ≤ 0.012). ICAintra changed by 1.8% (p = 0.179). Analyses of the relative changes between the intracerebral and extracerebral arteries revealed significantly larger constriction of the extracerebral than of the intracerebral (MCA, BA, ICAintra) arteries (p < 0.000001).
Conclusion
Sumatriptan constricts more extracerebral than intracerebral arteries. We suggest that sumatriptan exerts its anti-migraine action outside the blood-brain barrier by constricting the extracerebral arteries and blocking the nociceptive inputs from sensory afferents.
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